APOE and Alzheimer disease: Furthermore, the conversion rate was 15.2% within a mean of 1.6 years, and a positive scan of 18F-Florbetapir PET was associated with a greater hazard for AD conversion, which was affected by APOE4 and baseline cognitive status [25].